Risperidone for treatment of aggressive-impulsive behaviour in children and adolescents with low-average-intelligence, learning disability and mild mental disorder;Risperidon zur behandlung aggressiv-impulsiven verhaltens bei kindern und jugendlichen mit intelligenz im unteren durchschnittsbereich, lernbehinderung und leichter geistiger behinderung

Nervenheilkunde

Volumn 22, Issue 2, 2003, Pages 93-97

  Fegert, Jörg M ^a   Findling, R ^b   DeSmedt, G ^c  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Aggressive behaviour disorder; Atypical neuroleptics; Mental retardation; Risperidon

Indexed keywords

RISPERIDONE;

ADOLESCENT; AGGRESSION; ARTICLE; BEHAVIOR DISORDER; CHILD; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERPROLACTINEMIA; IMPULSIVENESS; INTELLIGENCE; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; SIDE EFFECT; SOCIAL BEHAVIOR; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0037248197     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Aman MG, Madrid A. Atypical antipsychotics in persons with developmental disabilities. Mental retardation and developmental disabilities research 1999; 5: 253-63.
2. Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol Psychiatry 1999; 40: 57-87.
3. Baumeister AA, Todd ME, Sevin JA. Efficacy and specifity of pharmacological therapies for behavioral disorders in persons with mental retardation. Clin Neuropharmacol 1993; 16: 271-94.
4. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P. et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001; 62: 239-48.
5. Campbell M, Cohen IL, Small AM. Drugs in aggressive behavior. J Am Acad Child Psychiatry 1982; 21: 107-17.
6. Campbell M, Perry R, Green WH et al. Behavioral efficacy of haloperidol and lithium carbonate: A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984; 41: 650-6.
7. Campbell M, Adams PB, Small AM et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34: 445-53.
8. Cohen S, Fitzgerald B, Okos A et al. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Journal of Clinical Psychiatry 2003; 64: 60-2.
9. Fegert JM, Häßler F, Rothärmel S (Hrsg.). Atypische Neuroleptika in der Jugendpsychiatrie. Stuttgart: Schattauer 1999.
10. Findling RL, McNamara NK, Branicky LA et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 509-16.
11. HäßBIer F. Psychopharmakotherapie bei geistig Behinderten. Psychopharmakotherapie 1998; 5: 76-80.
12. Häßler F, Fegert JM. Moderne Behandlungskonzepte für Menschen mit geistiger Behinderung. Stuttgart: Schattauer 2000.
13. Loeber R, Burke JD, Lahey BB et al. Oppositional defiant and conduct disorder: a review of the past 10 years, Part I. J Am Acad Child Adolesc Psychiatry 2000; 39: 1468-84.
14. McCracken JT et al. Risperidone in children with autism and serious behavioural problems. N Engl J Med 2002; 347: 314-21.
15. Meins W, Auwetter J, Krausz M et al. Behandlung mit Psychopharmaka in unterschiedlichen Einrichtungen für geistig Behinderte. Nervenarzt 1993; 64: 451-5.
16. Malone RP, Delaney MA, Luebbert JF et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000; 57: 649-54.
17. Patel NC, Sanchez RJ, Johnsrud MT et al. Trends in antipsychotic use in children and adolescents: 1996-2000. Presented at the New Clinical Drug Evaluation Annual Meeting, June 10-13, 2002, Boca Raton, Florida.
18. Schüler-Springorum M, Hebebrand J, Wehmeier PM et al. Führt Topiramat zu Gewichtsabnahme bei neuroleptikabedingtem Übergewicht? Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 2002; 30: 51-8.
19. Tiedtke K, Haury S, Eichhorn C et al. Einsatz einer kombinierten Psychopharmakotherapie mit Risperidon und Methylphenidat bei Kindern, die eine expansive Verhaltensstörung und eine leichte Intelligenzminderung aufweisen. In: Lehmkuhl U (Hrsg.): Seelische Krankheit im Kindes- und Jugendalter (Abstracts). Göttingen; Vandenhoeck & Ruprecht 2002.
20. van Bellinghen M, de Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebocontrolled pilot trial. J Child Adolesc Psychopharmacol 2001; 1: 5-13.
21. Wolraich ML, Hannah JN, Pinnock et al. comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 1996; 35: 319-24.